Local Coverage Article Response to Comments

Response to Comments: Platelet Rich Plasma


Expand All | Collapse All

Contractor Information

Article Information

General Information

Article ID
Article Title
Response to Comments: Platelet Rich Plasma
Article Type
Response to Comments
Original Effective Date
Retirement Date
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2022 American Dental Association. All rights reserved.

Copyright © 2022, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

As an important part of Medicare Local Coverage Determination (LCD) development, National Government Services solicits comments from the provider community and from members of the public who may be affected by or interested in our LCDs. The purpose of the advice and comment process is to gain the expertise and experience of those commenting.

We would like to thank those who suggested changes to the Platelet Rich Plasma LCD. The official notice period for the final LCD begins on June 10, 2021, and the final determination will become effective on August 1, 2021.

Response To Comments


One commenter indicated there was “clinical trial evidence that supports coverage of Platelet Rich Plasma for “specific conditions” and then went on to explain how PRP has been studied to be “an effective treatment for knee osteoarthritis.” The presenter acknowledged the clinical studies have “heterogeneity of PRP preparation” and variability for the “follow up duration” in the studies and further acknowledged these variabilities created difficulty in “interpreting the results differently”.

We disagree. The clinical utility of the PRP for knee osteoarthritis has not been shown to be reasonable or necessary and assessing PRP for knee osteoarthritis cannot be assessed based only on the non-inferiority, effectiveness or superior effect compared with hyaluronic acid or acetaminophen.

Furthermore, the issue in the medical literature is more than just the variability in the PRP preparation and follow up duration. The clinical studies have also shown to be have potential bias in the clinical trials, a variability between the number of injections, an interval variability between the injections, a variability between the volume of PRP injected, the duration between the injections, the frequency of the injections, and the type of the PRP injected.

The coverage determination will remain non-covered for all platelet rich plasma injections and/or applications as a means of managing musculoskeletal injuries and/or joint conditions.


Associated Documents

Related Local Coverage Documents
L38937 - Platelet Rich Plasma
Related National Coverage Documents
Public Versions
Updated On Effective Dates Status
06/04/2021 08/01/2021 - N/A Currently in Effect You are here